Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

New additions to the Adis Journal Club – December update

Drugs & Therapy Perspectives

Browse December's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

ACR Convergence 2021

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

Question mark illustration

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.

ACR Convergence 2021

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

Inflamed joint pain (illustrative with model)

Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis (RA) with inadequate responses to methotrexate and tumor necrosis inhibitor (TNF) inhibitor therapy in the latest CREDO findings. Read now

ACR Convergence 2021

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

The Great Debate

In “The Great Debate”, experts discussed which new add-on treatment option should be used first for patients with active lupus nephritis despite conventional therapy. Read now

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Inflammatory arthritis

18-11-2021 | Rheumatoid arthritis | News

Excess mortality gap closing, but not for all rheumatic diseases

Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

IN FOCUS | JAK inhibitors

10-11-2021 | ACR 2021 | Conference coverage | News

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with rheumatoid arthritis at high cardiovascular risk, show the ORAL Surveillance results.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

IN FOCUS | COVID-19 & rheumatic disease

20-10-2021 | COVID-19 | News

Data favor TNF inhibitor monotherapy for IMIDs during COVID-19 pandemic

TNF inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Podcasts

Interviews with expert rheumatologists on patient care

Image Credits